Wnt3a protects SH-SY5Y cells against 6-hydroxydopamine toxicity by restoration of mitochondria function by unknown
Translational 
Neurodegeneration
Wei et al. Translational Neurodegeneration  (2015) 4:11 
DOI 10.1186/s40035-015-0033-1RESEARCH Open AccessWnt3a protects SH-SY5Y cells against
6-hydroxydopamine toxicity by restoration
of mitochondria function
Lei Wei1,2*, Li Ding3, Ming-shu Mo2, Ming Lei2, Limin Zhang2, Kang Chen5 and Pingyi Xu2,4*Abstract
Background: Wnt/β-catenin signal has been reported to exert cytoprotective effects in cellular models of several
diseases, including Parkinson’s disease (PD). This study aimed to investigate the neuroprotective effects of actived
Wnt/β-catenin signal by Wnt3a on SH-SY5Y cells treated with 6-hydroxydopamine (6-OHDA).
Methods: Wnt3a-conditioned medium (Wnt3a-CM) was used to intervene dopaminegic SH-SY5Y cells treated with
6-OHDA. Cell toxicity was determined by cell viability and lactate dehydrogenase leakage (LDH) assay. The mitochondria
function was measured by the mitochondrial membrane potential, while oxidative stress was monitored with intracellular
reactive oxygen species (ROS). Western blot analysis was used to detect the expression of GSK3β, β-catenin as well as Akt.
Results: Our results showed that 100 μM 6-OHDA treated for 24 h significantly decreased cell viability and mitochondrial
transmembrane potential, reduced the level of β-catenin and p-Akt, increased LDH leakage, ROS production and the ratio
of p-GSK3β (Tyr216) to p-GSK3β (Ser9). However, Wnt3a-conditioned medium reversing SH-SY5Y cells against
6-OHDA-induced neurotoxicity by reversing these changes.
Conclusions: Activating of Wnt/β-catenin pathway by Wnt3a-CM attenuated 6-OHDA-induced neurotoxicity significantly,
which related to the inhibition of oxidative stress and maintenance of normal mitochondrial function.
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Parkinson’s disease (PD), characterized by loss of dopamin-
ergic neurons in substantia nigra, is the second most
common neurodegenerative diseases in elderly people.
Studies have shown that several mechanisms are involved in
pathogenesis of PD including oxidative stress, mitochondrial
dysfunction and elevated brain iron levels [1–3]. Although
much research has helped to elucidate the pathogenesis of
PD, the precise etiology and pathogenesis of the disease still
remain unknown. Moreover, Current treatments for PD
predominantly rely on pharmacotherapy to improve the
symptoms of movement disorder, but little efficacy in
preventing disease progression. Therefore neuroprotective
therapy may play a key role in the therapeutic strategy of PD.* Correspondence: weilei068@163.com; pingyixu@sina.com
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creativecommons.org/publicdomain/zero/1.0/Wnt signaling pathway is an autocrine-paracrine signal
transduction pathway which has been demonstrated to
participate in embryonic development, cell differenti-
ation and ontogenesis [4–7]. A main Wnt signaling
pathway branch is the wnt/β-catenin pathway, which ini-
tiates with Wnt proteins binding to Frizzled receptors
and activates Dishevelled. Activation of Dishevelled
results in inhibition of glycogen synthase kinase-3β
(GSK3β), which in turn causes stabilization of β-catenin.
Stabilized β-catenin accumulates and is taken into the
nucleus where it regulates expression of numerous genes
[8]. Extensive research has confirmed the vital role of
Wnt signaling in midbrain dopaminergic neuronal
development [9, 10]. For example, Wnt1 and Wnt3a,
which exert effects by Wnt/β-catenin pathway, are
key regulators in the development of dopaminergic
neurons [9].
The cellular protective effects of Wnt/β-catenin path-
way have been demonstrated in animal and cellularle distributed under the terms of the Creative Commons Attribution License
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cerebral ischemia as well as PD [11–14]. Our previous
study hasdemonstrated that Wnt/β-catenin signal is
inhibited in SH-SY5Y cells treated with 6-OHDA, a
cellular model of PD, while activation of Wnt/β-catenin
signal by exogenous Wnt1 could protect cells by restor-
ing mitochondria and endoplasmic reticulum function
[15]. However, the precise mechanism for the pathogen-
esis of the disease remains unknown. In this study, we
report that Wnt3a-conditioned medium (Wnt3a-CM)
protected cells from 6-OHDA neurotoxicity by a mechan-
ism that involved maintenance of normal mitochondrial.
Methods
Cell culture
Human neuroblastoma SH-SY5Y cells were obtained from
American Type Culture Collection (ATCC, Manassas, VA,
U.S.A.), maintained in DMEM with high glucose
(Invitrogen, USA) supplemented with 10 % fetal bovine
serum (FBS, Invitrogen), and cultured in a humidified
incubator with 5 % CO2 at 37 °C. Cells with 20–30
passages were used. For experiments, cells were seeded at
a density of 1 × 105 /cm2 in the plastic flasks or plates.
Conditioned media containing Wnt3a (Wnt3a-CM) were
prepared from mouse L cells (ATCC) stably expressing
Wnt3a. Control conditioned media were obtained from
parental L cells (Ctrl-CM). Different proportions of Ctrl-
CM or Wnt3a-CM were performed according to corre-
sponding experiments.
Cell viability assay
SH-SY5Y cells were seeded in a 96-well plate at a density
of 1 × 103 cells per well. After attachment, cells were
treated with 100 μM 6-OHDA, Ctrl-CM (10–80 %) or
Wnt3a-CM (10–80 %) for 24 h. After treatment, cells
were incubated with 0.5 mg/mL MTT (Sigma-Aldrich,
USA) for 4 h at 37 °C [16]. Following aspiration of the
MTT solution, the same volume of DMSO was addedFig. 1 Treatment with Wnt3a-CM or Ctrl-CM didn’t change SH-SY5Y cell via
or Wnt3a-CM, cell viability was measured by MTT assay. Data were presentinto each well to dissolve the purple formazan crystals.
Absorbance was read in a microtiter plate reader at
490 nm. Cell viability was expressed as a percentage of
the absorbance from control cells. The toxic effects of 6-
OHDA to SH-SY5Y cells were also detected by measur-
ing the leakage of the cytosolic enzyme LDH to the
culture medium using a colorimetric LDH assay kit
(KeyGen, China) according to the manufacturer’s instruc-
tions [17]. Briefly, after 100 μM 6-OHDA added, 20 μl of
cell medium were added into basic solution to measure
extracellular LDH activity, which could catalyze the
conversion of lactate to pyruvate, which then reacted with
2,4-dinitrophenylhydrazine to give the brownish red color.
The absorbance was measured at a wavelength of 440 nm
by colorimetric assay, and the LDH leakage was expressed
as the percentage versus control cells.
Measurement of mitochondrial transmembrane potential
(MMP) and intracellular ROS production
Changes in the mitochondrial membrane potential with
various treatments in SH-SY5Y cells were measured by
rhodamine-123 or DCFH-DA using a fluorescence spec-
trophotometer [18]. Briefly, cells were treated with 6-
OHDA, Ctrl-CM and Wnt3a-CM for 24 h and then
incubated with rhodamine-123 (Sigma-Aldrich, USA) or
DCFH-DA (Sigma-Aldrich, USA) in a final concentra-
tion of 10 or 25 μmol/L respectively for 30 min at 37 °C.
After washing twice with HEPES buffer saline (Invitrogen,
USA), fluorescence was recorded at 488 nm excitation
and 523 nm emission wave-lengths. Each field of cells was
photographed using a fluorescence microscopy.
Western blot analysis
The immunoblotting was performed in accordance with
a standard procedure [16, 19]. The following primary
antibodies were used: rabbit anti-β-catenin (1:1000
dilution, Abcam, Cambridge, UK), rabbit anti-p-GSK3β
(Ser9) (1:1000 dilution, CST, USA), rabbit anti-p-GSK3βbility. SH-SY5Y cells were treated with different proportion of Ctrl-CM
ed as mean ± SD from four independent experiments
Fig. 2 Effects of Wnt3a-CM on viability of SH-SY5Y cells treated with
6-OHDA. SH-SY5Y cells were pretreated with different proportion of
Wnt3a-CM (10–80 %) prior to 6-OHDA (100 μM) treatment for 24 h
and cell viability assessed using the MTT assay. The data are
expressed as percentage relative to Ctrl-CM group and presented as
mean ± SD from four independent experiments. *P < 0.05 compared
to the control, †P < 0.05 compared to 6-OHDA treated group
Fig. 3 Effects of Wnt3a-CM on LDH leakage of SH-SY5Y cells treated
with 6-OHDA. SH-SY5Y cells were pretreated with different proportion
of Wnt3a-CM (10–80 %) prior to 6-OHDA (100 μM) treatment for 24 h
and LDH assay was performed to determine the degree of cell injury.
The data are expressed as percentage relative to Ctrl-CM group and
presented as mean ± SD from four independent experiments. *P < 0.05
compared to the control, †P< 0.05 compared to 6-OHDA treated group
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(Ser473) (1:1000 dilution, Millipore, USA), mouse anti-
β-actin (1:1000 dilution, Millipore, USA). Proteins were
detected with the SuperSignal® West Pico Chemilumines-
cent Substrate (Thermo Fisher Scientific Inc., IL, USA)
and membranes were exposed to X-ray films (Fujifilm
Corporation, Japan), which were scanned and analyzed by
using the Quantity One v4.62 for Windows software
(Biorad, CA, USA).
Statistical analysis
Results were presented as mean ± SD. One-way analysis of
variance (ANOVA) followed by Student–Newman–Keuls
test was used to compare differences between means in
more than two groups. The level of significance was set at
P < 0.05. All the statistical analyses were performed with
SPSS 12.0 for windows (SPSS Inc., Chicago, IL, USA).
Results
Wnt3a-CM attenuated 6-OHDA-induced cell injury
Our previous studies have confirmed that treatment with
6-OHDA for 24 h caused a concentration-dependent
reduction in cell viability and a concentration-dependent
increase in LDH release in dopaminergic SH-SY5Y cells
[15]. According to our previous results, a 100 μM 6-
OHDA was chosen for the following experiments.
We then tested the effect of Wnt3a-CM on SH-SY5Y
cells, and found that treatment with Wnt3a-CM or Ctrl-
CM at proportion of 10–80 % didn’t obviously change
the cell viability (Fig. 1). Thus, Ctrl-CM at a proportion
of 40 % was used as control and we investigated whetherWnt3a-CM could attenuate the toxic effect of 6-OHDA
on SH-SY5Y cells. Wnt3a-CM was added to the cultures
at different proportion 20 min prior to 6-OHDA. Cells
pre-treated with Wnt3a-CM were partially protected
against 6-OHDA toxicity. Treatment with 100 μM 6-
OHDA for 24 h decreased the cell viability to ~50 %
compared with Ctrl-CM group. However, when cells
were pre-treated with Wnt3a-CM the reduction of cell
viability was ameliorated. Specifically, the level of cell
viability increased to 62.16 ± 3.71 % of the control value
when 20 % of Wnt3a-CM was used and that was up to
76.35 ± 5.00 % when 40 % of Wnt3a-CM was added.
Then the cell viability of higher proportion of Wnt3a-
CM (60 and 80 %) was reduced to 74.64 ± 5.21 and
75.79 ± 4.71 respectively (Fig. 2). Similarly, pretreatment
of 20, 40, 60 and 80 % Wnt3a-CM could significantly
inhibit LDH release induced by 6-OHDA (Fig. 3).Wnt3a-CM antagonized 6-OHDA-induced MMP
and ROS production
It is generally accepted that the 6-OHDA-induced
neuronal apoptosis is mediated by the mitochondrial
dysfunction. Markers of mitochondria function, such
as mitochondrial membrane potential are often used
to monitor the cell apoptosis. In the experiment, there
was a significant reduction of MMP in 6-OHDA-treated
SH-SY5Y cells. However, a partial restoration of MMP was
observed in the cells treated with Wnt3a-CM at a propor-
tion of 40 % (Fig. 4a and 4c). In consideration of ROS
Fig. 4 Mitochondrial membrane potential (MMP) AND intracellular ROS production. SH-SY5Y cells were treated with Ctrl-CM, Ctrl-CM + 6-OHDA
(100 μM) or Wnt3a-CM (40 %) 20 min prior to 6-OHDA for 24 h, MMP (a) and intracellular ROS (b) were photographed by a fluorescence microscopy.
Results of MMP (c) and intracellular ROS (d) are detected by a fluorescence spectrophotometer and expressed as relative fluorescent intensity. Data
were presented as mean ± SD from four independent experiments. *P< 0.05 compared to Ctrl-CM group, †P< 0.05 compared to Ctrl-CM+ 6-OHDA group
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by 6-OHDA [20], we further examined if Wnt3a-CM
inhibit 6-OHDA-induced cell apoptosis by suppressing
ROS production. As shown in Fig. 4b and d, 6-OHDA
treatment alone for 24 h induced about 2-fold increase in
ROS level compared to the control group, whereas pre-
treatment with 40 % Wnt3a-CM exhibited an inhibitive
effect of ROS production from cells.Wnt3a-CM activated Wnt/β-catenin pathway
To verify the activation effect of Wnt3a-CM on Wnt/β-
catenin pathway, western blot was used to detect the
expression of p-GSK3β (Ser9), p-GSK3β (Tyr216) and
β-catenin in SH-SY5Y cells. Because the activity of
GSK3β is regulated negatively by the phosphorylation of
serine 9 (Ser9) and positively by the phosphorylation of
tyrosine 216 (Tyr216) [21], the ratio of p-GSK3β (Tyr216)
Wei et al. Translational Neurodegeneration  (2015) 4:11 Page 5 of 8to p-GSK3β (Ser9) can be used to monitor the activity of
GSK3β. We found that treatment of 100 μM 6-OHDA for
24 h increase the ratio of p-GSK3β (Tyr216) to p-GSK3β
(Ser9), and decrease β-catenin level. However, pretreat-
ment with Wnt3a-CM reverse these changes induced by
6-OHDA treatment (Fig. 5a, b and c).Fig. 5 Change of related signal proteins in the cytoprotective effect of Wn
with vehicle, 6-OHDA (100 μM), Ctrl-CM, or Wnt3a-CM (40 %) 20 min prior
GSK3β and β-catenin (a) were detected by Western blot with β-actin as int
software and normalized to the expression of β-actin in SHSY5Y cells. The r
of β-catenin (c) were expressed in histogram. Data were presented as mea
compared to Ctrl-CM + 6-OHDA groupWnt3a-CM reversed 6-OHDA-induced
Akt down-regulation
Investigation has documented that Wnt signal rely upon
PI3K/Akt activation to support the cell survival [22].
Here we detected the level of p-Akt (Ser473) protein,
an active form of Akt, in SH-SY5Y cells treated witht3a-CM in Sh-SY5Y treated with 6-OHDA. SH-SY5Y cells were treated
to 6-OHDA for 24 h, the protein levels of 2 phosphorylation forms of
ernal control. The band intensities were measured by Quantity One
atio of p-GSK3β (Tyr216) to p-GSK3β (Ser9) (b) and the relative levels
n ± SD of 3 experiments. *P < 0.05 compared to the control, †P < 0.05
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Akt protein level in 6-OHDA treated group were de-
creased to ~54 % compared with control group, while
that in cells pretreatment of Wnt3a-CM was ~88 %
(Fig. 6), which suggested that treatment of Wnt3a might
reverse the down-regulation of PI3K/Akt pathway by 6-
OHDA treatment.
Discussion
This study investigated the protective effects of Wnt3a-
conditioned medium on a cellular model of PD and
showed that Wnt/β-catenin pathway was inhibited after
treatment of 100 μM 6-OHDA for 24 h, evidenced by
the decreased β-catenin level and increased GSK3β
activity. Moreover, activating Wnt/β-catenin pathway by
Wnt3a-CM was found to attenuate 6-OHDA-induced
neurotoxicity in SH-SY5Y cells through restoration of
mitochondria transmembrane potential and reducing
ROS production, indicating the Wnt/β-catenin pathway
related to the maintenance of mitochondrial function.
SH-SY5Y cell line chosen in this study was considered
for its expression of tyrosine hydroxylase (TH) simulatingFig. 6 Change of p-Akt level in the cytoprotective effect of Wnt3a-CM in Sh-SY
(100 μM), Ctrl-CM, or Wnt3a-CM (40 %) 20 min prior to 6-OHDA for 24 h, the p
internal control. The relative band intensities of p-Akt (b) were measured by Qu
SHSY5Y cells. Data were presented as mean ± SD of 3 experiments. *P< 0.05 coto dopaminergic neurons [23]. As an endogenous oxi-
dative metabolite of dopamine, 6-OHDA could inhibit
the mitochondrial respiratory chain through inhibiting
Complex I, uncoupling oxidative phosphorylation and
collapsing mitochondrial membrane [24–26]. It is thought
that 6-OHDA induces toxicity that mimics the neuro-
pathological and biochemical characteristics of PD in SH-
SY5Y cells [27].
Wnt3a is one of the Wnt ligands that activate the ca-
nonical Wnt pathway [28]. Because the purified Wnt3a
is unstable, the Wnt3a conditioned medium is com-
monly used for the activation of the canonical Wnt path-
way in in vitro experiments [29]. Recently, L’Episcopo
et al. found the β-catenin protein acts as a pro-survival
factor for mesencephalic TH+ neurons [14]. Meanwhile,
Dickkopf-1 (DKK1), a negative regulator of the Wnt/
β-catenin signaling pathway, was found to promote
apoptosis of SH-SY5Y cells [30]. Dun Y and col-
leagues also found that induction of DKK1 contrib-
utes to the MPP+-induced neurotoxicity in PC12 cells
via inhibition of the canonical Wnt pathway, and inhib-
ition of DKK1 which could rescue the Wnt pathway might5Y treated with 6-OHDA. SH-SY5Y cells were treated with vehicle, 6-OHDA
rotein levels of p-Akt (a) were detected by Western blot with β-actin as
antity One software and normalized to the expression of β-actin in
mpared to the control, †P< 0.05 compared to Ctrl-CM + 6-OHDA group
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confirmed that Wnt3a-CM increase the β-catenin protein
level, which might contribute to the protective effect on
cells. Moreover, our previous study uncovered that down-
regulation of GSK3β, also a central component of the
Wnt/β-catenin pathway, attenuate 6-OHDA-induced
neuronal death and apoptosis [25]. The inhibition of
GSK3β was reported to be linked with the attenuation
of oxidative stress [32]. Data in this study confirmed
that Wnt3a-CM inhibited the activity of GSK3β by
increasing the phosphorylation at site Ser9 and de-
creasing the phosphorylation at site Tyr216.
Due to the mitochondrial dysfunction was consid-
ered a key factor in PD onset, we also measured
MMP and ROS production from the SH-SY5Y cells
in vitro. Mitochondria is the major site of ROS pro-
duction and also prime target of oxidative molecular
damage, the consequent formation of ROS further
damages the mitochondrial membrane and such dam-
ages are implicated as key events in the pathogenic
cascades leading to apoptosis [24, 33]. Shin SY and
colleagues reported that stimulation of Wnt signaling
by Wnt3a-CM inhibits H2O2-induced mitochondrial
cytochrome C release and DNA fragmentation L1210
cells [34]. In this experiment, we found that Wnt3a-
CM eliminated ROS production, stabilized mitochon-
drial transmembrane potential in SH-SY5Y cells.
PI3K and Akt are central to the regulation of cell
growth and survival throughout the body [35, 36]. Akt,
which is also known as protein kinase B (PKB), is a key
molecule in growth factor signaling pathways mediating
neuronal survival in both development and disease in
multiple paradigms, including resistance against oxida-
tive insults in the brain and protection of mitochondria
function [37, 38]. Here our data showed that Wnt3a-CM
reverse the down-regulation of p-Akt (Ser473) which
is the active form of Akt caused by 6-OHDA treat-
ment, clearly suggesting the mediation of the PI3K/
Akt pathway in the protective effect of Wnt3a-CM on
6-OHDA-induced cell injury.
In conclusion, our data showed that activating of Wnt/β-
catenin pathway by Wnt3a attenuated 6-OHDA-induced
neurotoxicity, which involved in the mechanism about the
inhibition of oxidative stress relate to the mitochondrial
functional maintenance. These result may provide a new
potential therapeutic target for Parkinson’s diseases.
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